期刊文献+

HIV疫苗小鼠免疫原性检测方法的初步建立 被引量:2

Development of A Method for Determination of Immunogenicity of HIV Vaccine in Mice
原文传递
导出
摘要 目的初步建立HIV疫苗小鼠免疫原性检测方法,并对HIV疫苗进行免疫原性评价。方法选择一种HIVDNA疫苗(D)、2种重组痘苗载体HIV疫苗(M和R),分别免疫BALB/c小鼠,6周后分离血清和脾淋巴细胞,采用ELISOPT和胞内因子染色法检测细胞因子分泌情况,MTS法检测淋巴细胞增殖反应,ELISA法检测血清中抗-HIVIgG和IgA抗体水平。结果D、M和R疫苗均可诱导小鼠产生广泛的免疫应答,ELISPOT法可检出脾细胞分泌IFNγ、IL-2、IL-4和IL-6;胞内因子染色可检出IFNγ、IL-2和IL-4的分泌;D和M组脾淋巴细胞增殖试验阳性数高于R组;D、M和R组血清抗-HIVIgG抗体分别有0/5、1/5和5/5小鼠阳转,各组均未检出血清抗-HIVIgA。结论已初步建立了HIV疫苗小鼠免疫原性检测方法。 Objective To preliminarily develop a method for determination of immunogenicity of HIV vaccine in mice and evaluate the immunogenicity. Methods BALB / c mice were immunized with one kind of HIV DNA vaccine(D)and two kinds of recombinant vaccinia virus-based HIV vaccines(M and R)respectively, and their sera and splenic lymphocytes were separated 6 weeks later. The secretions of cytokines in splenic lymphocytes were determined by ELISOPT and intracellular cytokine staining, and the proliferation of lymphocytes by MTS method. The anit-HIV IgG and IgA levels in sera were determined by ELISA. Results All the vaccines induced a broad of immune responses in mice. ELISPOT proved the secretions of IFNγ, IL-2, IL-4 and IL-6, and intracellular cytokine staining proved the secretions of IFNγ, IL-2 and IL-4 in splenic lymphocytes. The numbers of splenic lymphocytes positive in proliferation test of mice immunized with vaccines D and M were larger than that with vaccine R. Anti-HIV IgG were detected in 0 / 5, 1 / 5 and 5 / 5 of mice immunized with vaccines D, M and R respectively, while no anti-HIV IgA were detected. Conclusion A method for determination of immunogenicity of HIV vaccine in mice was preliminarily developed.
出处 《中国生物制品学杂志》 CAS CSCD 2010年第4期385-388,共4页 Chinese Journal of Biologicals
基金 "十一五"科技重大专项(2009ZX10004-801)
关键词 HIV 疫苗 免疫原性 HIV Vaccine Immunogenicity
  • 相关文献

参考文献10

  • 1Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis, 2006, 43 (4): 500- 511.
  • 2Johnston MI, Fauci AS. An HIV vaccine-evolving concepts. N Engl J Med, 2007, 356(20): 2073-2081.
  • 3Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis, 2005, 191 (5): 654-665.
  • 4Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, 2008, 372(9653): 1881-1893.
  • 5Trinvuthipong C. Thailand's prime-boost HIV vaccine phase III. Science, 2004, 303(5660): 954-955.
  • 6McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet, 2008, 372(9653): 1894-1905.
  • 7Dubey'S, Clair J, Fu TM, et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr, 2007, 45 ( 1 ): 20-27.
  • 8Belyakov IM, Ahlers JD, Nabel GJ, et al. Generation of functionally active HIV-1 specific CD8^+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology, 2008, 381(1): 106-115.
  • 9St John EP, Zariffard MR, Martinson JA, et al. Effect of mucosal fluid from women with bacterial vaginosis on HIV trans-infection mediated by dendritic cells . Virology, 2009, 385 ( 1 ): 22-27.
  • 10Chong H, Hong K, Zhang C, et al. Genetic and neutralization properties of HIV-1 env clones from subtype B / BC / AE infections in China. J Acquir Immune Defic Syndr, 2008, 47(5): 535- 543.

同被引文献9

  • 1刘颖,段丹丽,彭虹,唐海丽,刘沙,张宁,王宁,刘建源,邵一鸣.HIV复制型痘苗病毒载体疫苗免疫原性分析[J].中华实验和临床病毒学杂志,2004,18(3):281-283. 被引量:9
  • 2杨春红,宋长征.HIV/艾滋病疫苗:策略及展望[J].生物技术通讯,2006,17(1):96-98. 被引量:2
  • 3熊仲良,邓小红,曾政.一种有效的免疫学检测技术——ELISPOT[J].动物医学进展,2006,27(9):101-104. 被引量:3
  • 4Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand [J]. Infect Dis, 2006, 194 (12): 1661-1671.
  • 5Americo JL, Moss B, Earl PL. Identification of wild-derived in-bred mouse strains highly susceptible to monkeypox virus infec-tion for use as small animal models [J]. J Virol, 2010, 84 (16): 8172-8180.
  • 6Majid A M, Ezelle H, Shah Set al. Evaluating replication-defective ve- sicular stomatitis virus as a vaccine vehicle [ J ]. J Viro|, 2006;80 (14) :6993-7008.
  • 7Samri A, Durier C, Urrutia A et al. Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specif- ic T cells with agamma interferon enzyme-linked immunospot assay [ J ]. Clin Vaccine Immunol,2006 ; 13 (6) :684-697.
  • 8Dubey S, Clair J, Fu T M et al. Detection of HIV vaccine-induced cell- mediated immunity in HIV-seronegative clinical trial participants using an optimizeld and validated enzyme-linked immunospot assay [ J ]. Ac- quir Immune Defic Syndr,2007 ;45 ( 1 ) :20-27.
  • 9Zoe Moodie , Yunda Huang, Lin Gu et al. Statistical positivity criteria for the analysis of ELISPOT assay data in HIV-1 vaccine trials[J]. J Immunol Methods ,2006 ;315 (1-2) : 121-132.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部